Table 1.
Cancer patient's characteristics.
| With T cell responses |
Without T cell response |
|||
|---|---|---|---|---|
| Solid tumours (n = 14) | Haematological malignancies (n = 4) | Solid tumours (n = 14) | Haematological malignancies (n = 7) | |
| Patient characteristics n (%) | ||||
| Age - median (year) | 70 | 73 | 69 | 59 |
| [Range] | [51–75] | [54–80] | [48–84] | [23–73] |
| <65 | 4 (28.6) | 1 (25.0) | 6 (42.9) | 4 (57.1) |
| 65–74 | 8 (57.1) | 2 (50.0) | 5 (35.7) | 3 (42.9) |
| >75 | 2 (14.3) | 1 (25.0) | 3 (21.4) | 0 (0) |
| Male | 7 (50.0) | 4 (100.0) | 5 (35.7) | 4 (57.1) |
| History of cancer n (%) | ||||
| Metastatic or late stage | 9 (64.3) | 1 (25.0) | 12 (85.7) | 2 (28.6) |
| Active anticancer treatment during 4 weeks before COVID infection | 10 (71%) | 3 (75.0) | 12 (85.7) | 1 (50) |
| Chemotherapy | 6 (42.9) | 0 (0.0) | 6 (42.9) | 0 (0.0) |
| Chemotherapy + immunotherapy | 0 (0.0) | 1 (25.0) | 1 (7.1) | 0 (0.0) |
| Immunotherapy | 2 (14.3) | 1 (25.0) | 1 (7.1) | 0 (0.0) |
| Targeted therapy | 1 (7.1) | 1 (25.0) | 4 (28.6) | 1 (50) |
| Hormonotherapy | 1 (7.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| COVID-19 n (%) | ||||
| Symptomatic | 12 (85.7%) | 4 (100.0) | 14 (100.0) | 7 (100.0) |
| Diagnostic of COVID-19 | ||||
| PCR | 8 (57.1) | 4 (100.0) | 11 (78.6) | 7 (100.0) |
| PCR+ >1 month | 0 (0.0) | 0 (0.0) | 3 (21.4) | 1 (14.3) |
| Serology | 6 (42.9) | 0 (0.0) | 3 (21.4) | 0 (0.0) |
| Time between COVID-19 infection and blood sample - median [range] in days | 70.5 [48–109] | 76.5 [49–92] | 62.5 [41–85] | 81.0 [48–119] |
| Immunological data | ||||
| PNN median (mm3) [Range] | 2 205 [1370–5250] | 2 935 [1410–5980] | 3 075 [902–9000] | 5 550 [900–35 000] |
| Missing | 4 | 0 | 0 | 1 |
| LDH median (UI/I) [Range] | 417 [207–464] | 199 [177–235] | 239 [61–341] | 444 [206–750] |
| Missing | 8 | 1 | 3 | 3 |
| Lymphopenia at the moment of COVID-19 infection (G/L) n (%) | 3 (42.8) | 2 (50.0) | 9 (64.3) | 2 (28.6) |
| Median [range] | 1 340 [600––2060] | 1 505 [690–2320] | 840 [300–1920] | 1 300 [580–1 900] |
| Missing | 7 | 0 | 0 | 1 |
| CD3 (%) [range] | 54.1 [26.4–89.4] | 65 [14.7–94.5] | 61.1 [31.7–87.5] | 54.4 [5.2–91.1] |
| CD4 (%) [range] | 51.3 [16.2–91.5] | 31.1 [4.3–51.4] | 52.2 [20.8–83.7] | 46.7 [8.3–66.2] |
| CD8 (%) [range] | 38.5 [7.1–69] | 58.9 [39.4–92.3] | 35.9 [13.8–63.3] | 48.4 [24.7–90.3] |
| CD4/CD8 (%) [range] | 2.4 [0.3–12.8] | 0.6 [0.04–1.3] | 2.0 [0.4–5.8] | 1.3 [0.09–2.6] |
| CD19 (%) [range] | 23.9 [1.5–58.3] | 27.3 [1–87.8] | 27.6 [2.9–75.1] | 18.7 [0.1–59.1] |
| Missing | 0 | 0 | 2 | 2 |